Josep  Llorens net worth and biography

Josep Llorens Biography and Net Worth

EVP of Haemonetics
Josep Llorens was named Executive Vice President, Global Manufacturing and Supply Chain in 2021, and is responsible for expanding manufacturing capacity, upscaling strategic sourcing, driving greater throughput and improving product quality. He joined Haemonetics as Senior Vice President, Global Manufacturing and Supply Chain in August 2018. Mr. Llorens brings over 30 years of experience in transforming supply chain, logistics and manufacturing operations to increase quality, improve customer satisfaction and reduce costs. Prior to joining Haemonetics, he was Senior Vice President, Industrial Strategy and Advanced Manufacturing Engineering Leader for Philips Healthcare Diagnostic Imaging. Before that position, he held various Operations and Supply Chain roles within the Philips healthcare business, delivering supply chain and operations optimization in Diagnostics and Treatment, Patient Monitoring and Cardiac Care businesses and leading global teams focused on continuous improvement. Mr. Llorens holds a bachelor's degree in Business Administration from University of Barcelona and a master's degree in Telecommunications Engineering from the Polytechnic University of Catalonia in Barcelona. He also received an Executive Certificate in Technology, Operations and Value Chain Management from the MIT Sloan School of Management.

What is Josep Llorens' net worth?

The estimated net worth of Josep Llorens is at least $1.46 million as of May 17th, 2024. Mr. Llorens owns 16,350 shares of Haemonetics stock worth more than $1,458,747 as of November 17th. This net worth evaluation does not reflect any other assets that Mr. Llorens may own. Additionally, Mr. Llorens receives a salary of $1,110,000.00 as EVP at Haemonetics. Learn More about Josep Llorens' net worth.

How old is Josep Llorens?

Mr. Llorens is currently 62 years old. There are 5 older executives and no younger executives at Haemonetics. Learn More on Josep Llorens' age.

What is Josep Llorens' salary?

As the EVP of Haemonetics Co., Mr. Llorens earns $1,110,000.00 per year. There are 2 executives that earn more than Mr. Llorens. The highest earning executive at Haemonetics is Mr. Christopher A. Simon, CEO, President & Director, who commands a salary of $3,260,000.00 per year. Learn More on Josep Llorens' salary.

How do I contact Josep Llorens?

The corporate mailing address for Mr. Llorens and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Josep Llorens' contact information.

Has Josep Llorens been buying or selling shares of Haemonetics?

Josep Llorens has not been actively trading shares of Haemonetics during the last quarter. Most recently, Josep Llorens sold 987 shares of the business's stock in a transaction on Monday, May 20th. The shares were sold at an average price of $95.08, for a transaction totalling $93,843.96. Following the completion of the sale, the executive vice president now directly owns 21,310 shares of the company's stock, valued at $2,026,154.80. Learn More on Josep Llorens' trading history.

Who are Haemonetics' active insiders?

Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.

Are insiders buying or selling shares of Haemonetics?

During the last twelve months, insiders at the medical instruments supplier sold shares 9 times. They sold a total of 33,828 shares worth more than $3,031,094.99. The most recent insider tranaction occured on July, 26th when insider Stewart W Strong sold 4,312 shares worth more than $393,038.80. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.

Information on this page was last updated on 7/26/2024.

Josep Llorens Insider Trading History at Haemonetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/20/2024Sell987$95.08$93,843.9621,310View SEC Filing Icon  
5/17/2024Sell822$94.82$77,942.0416,350View SEC Filing Icon  
7/18/2023Sell4,928$90.00$443,520.0018,463View SEC Filing Icon  
1/23/2023Sell2,391$90.00$215,190.0017,234View SEC Filing Icon  
5/19/2022Sell1,418$59.10$83,803.8017,335View SEC Filing Icon  
5/16/2022Sell107$56.10$6,002.7014,413View SEC Filing Icon  
9/7/2021Sell100$64.61$6,461.00View SEC Filing Icon  
5/19/2021Sell125$55.19$6,898.75View SEC Filing Icon  
9/8/2020Sell101$88.71$8,959.71View SEC Filing Icon  
9/5/2019Sell101$129.94$13,123.94View SEC Filing Icon  
See Full Table

Josep Llorens Buying and Selling Activity at Haemonetics

This chart shows Josep Llorens's buying and selling at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Haemonetics Company Overview

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $89.22
Low: $88.64
High: $91.43

50 Day Range

MA: $77.55
Low: $71.15
High: $93.38

2 Week Range

Now: $89.22
Low: $70.25
High: $97.97

Volume

564,400 shs

Average Volume

555,780 shs

Market Capitalization

$4.48 billion

P/E Ratio

37.02

Dividend Yield

N/A

Beta

0.32